神州细胞(688520) - 2024 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2024 reached ¥612,503,357.24, representing an increase of 86.30% compared to the same period last year[4] - Net profit attributable to shareholders was ¥74,197,374.04, with a significant improvement from a loss in the previous year[9] - The net profit after deducting non-recurring gains and losses was ¥156,999,273.17, driven by stable growth in product sales and cost control measures[9] - Total operating revenue for Q1 2024 reached RMB 612,503,357.24, a significant increase from RMB 328,779,509.01 in Q1 2023, representing an increase of approximately 86.1%[18] - Net profit for Q1 2024 was RMB 74,408,961.17, a turnaround from a net loss of RMB 153,348,003.27 in Q1 2023[19] - The total profit for Q1 2024 was RMB 74,408,961.17, compared to a total loss of RMB 153,348,003.27 in the same period last year[19] Cash Flow - The net cash flow from operating activities increased to ¥174,614,309.12, attributed to substantial revenue growth and increased cash receipts from sales[9] - Cash flow from operating activities for Q1 2024 was RMB 626,375,201.44, up from RMB 363,548,180.77 in Q1 2023, marking an increase of approximately 72.4%[19] - Net cash flow from operating activities for Q1 2024 was ¥174,614,309.12, a significant improvement from a negative cash flow of ¥121,991,794.43 in the same period last year[20] - Total cash inflow from financing activities reached ¥424,558,076.98, compared to ¥403,095,198.05 in Q1 2023[21] - The company reported a cash inflow of ¥673,087,944.90 from operating activities, up from ¥367,633,516.25 in Q1 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,827,779,969.88, reflecting a 4.02% increase from the end of the previous year[6] - Total current assets increased to RMB 1,124,763,080.85, up from RMB 1,060,347,468.42, representing a growth of approximately 6.1%[14] - Total non-current assets reached RMB 1,703,016,889.03, up from RMB 1,658,188,702.97, indicating an increase of around 2.7%[15] - Total liabilities amounted to RMB 3,350,034,051.24, slightly up from RMB 3,324,350,645.59, showing a marginal increase of about 0.8%[16] - Total equity attributable to shareholders decreased to RMB -516,112,769.36 from RMB -599,461,618.33, reflecting an improvement of about 13.9%[16] Research and Development - R&D investment totaled ¥244,484,611.26, accounting for 39.92% of revenue, a decrease of 42.20 percentage points from the previous year[6] - Research and development expenses for Q1 2024 amounted to RMB 237,334,271.65, slightly down from RMB 248,165,462.86 in Q1 2023, indicating a decrease of about 4.0%[18] - The company has no significant new product launches or technological developments reported during this quarter[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,223[10] - The largest shareholder, Lhasa Ailike Investment Consulting Co., Ltd., holds 60.90% of the shares[10] Financial Performance Metrics - The weighted average return on net assets was -13.30%, indicating a negative performance compared to the previous year[4] - The company reported a basic and diluted earnings per share of RMB 0.17 for Q1 2024, compared to a loss per share of RMB -0.34 in Q1 2023[19] - Tax expenses for Q1 2024 were RMB 4,041,783.18, compared to RMB 2,345,862.51 in Q1 2023, reflecting an increase of approximately 72.0%[18] - The company’s financial expenses for Q1 2024 were RMB 30,665,676.59, up from RMB 26,041,042.51 in Q1 2023, indicating an increase of about 17.0%[18] Government Support - The company received government subsidies amounting to ¥43,131,411.07, which positively impacted the financial results[7]